Sanofi-Aventis is a global healthcare company dedicated to improving health and well-being through the development and production of a wide range of pharmaceutical products and vaccines
With a strong focus on research and innovation, the company operates in various therapeutic areas, including diabetes, oncology, cardiovascular disease, central nervous system disorders, immunology, and rare diseases. Sanofi-Aventis also emphasizes the importance of vaccines in disease prevention and offers a portfolio that addresses public health needs. The company strives to enhance patients' quality of life by providing effective treatments and advancing healthcare solutions worldwide.
Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue.
Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.
Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge.
Sanofi has purchased 2.3% of its shares from L'Oréal SA as part of its share repurchase program. The €3 billion deal involves acquiring 29.6 million shares at €101.50 each, with cancellation expected by April 29, 2025.
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald Trump's executive order to withdraw from the global health body.
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market, Exscientia was acquired by another firm last year.
